BioNTech's Share Price Is Undervalued -- Market Talk

Dow Jones03-21

1413 GMT - BioNTech's share price offers an attractive entry point as the market undervalues the company's cancer drug pipeline potential as well as positive catalysts expected through 2025, Berenberg analysts say. The German biotech stock is trading near its six-month low, which doesn't reflect the potential of its cancer drug candidates, they say in a note. The analysts expect positive trial readouts, particularly for its individualized cancer vaccine platform and its HER2 antibody drug conjugate, to drive higher valuations through 2025. BioNTech's conservative 2025 guidance suggests planned cost-control and productivity measures, the analysts add. Shares fall 1.45% to 88.25 euros. (helena.smolak@wsj.com)

(END) Dow Jones Newswires

March 21, 2025 10:13 ET (14:13 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2521280188?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-21 22:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2521280188","market":"sh","top_or_hot":-1,"title":"BioNTech's Share Price Is Undervalued -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1413 GMT - BioNTech's share price offers an attractive entry point as the market undervalues the company's cancer drug pipeline potential as well as positive catalysts expected through 2025, Berenberg analysts say. The German biotech stock is trading near its six-month low, which doesn't reflect the potential of its cancer drug candidates, they say in a note. The analysts expect positive trial readouts, particularly for its individualized cancer vaccine platform and its HER2 antibody drug conjugate, to drive higher valuations through 2025. BioNTech's conservative 2025 guidance suggests planned cost-control and productivity measures, the analysts add. Shares fall 1.45% to 88.25 euros. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 21, 2025 10:13 ET (14:13 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech's Share Price Is Undervalued -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech's Share Price Is Undervalued -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-21 22:13</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1413 GMT - BioNTech's share price offers an attractive entry point as the market undervalues the company's cancer drug pipeline potential as well as positive catalysts expected through 2025, Berenberg analysts say. The German biotech stock is trading near its six-month low, which doesn't reflect the potential of its cancer drug candidates, they say in a note. The analysts expect positive trial readouts, particularly for its individualized cancer vaccine platform and its HER2 antibody drug conjugate, to drive higher valuations through 2025. BioNTech's conservative 2025 guidance suggests planned cost-control and productivity measures, the analysts add. Shares fall 1.45% to 88.25 euros. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 21, 2025 10:13 ET (14:13 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美国抗疫概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2521280188","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2521280188","pubTimestamp":1742566380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1413 GMT - BioNTech's share price offers an attractive entry point as the market undervalues the company's cancer drug pipeline potential as well as positive catalysts expected through 2025, Berenberg analysts say. The German biotech stock is trading near its six-month low, which doesn't reflect the potential of its cancer drug candidates, they say in a note. The analysts expect positive trial readouts, particularly for its individualized cancer vaccine platform and its HER2 antibody drug conjugate, to drive higher valuations through 2025. BioNTech's conservative 2025 guidance suggests planned cost-control and productivity measures, the analysts add. Shares fall 1.45% to 88.25 euros. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","BK4588":"碎股","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","BK4535":"淡马锡持仓","BNTX":"BioNTech SE","BK4585":"ETF&股票定投概念","BK4139":"生物科技"},"translate_title":"BioNTech股价被低估——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":0.9},"content_text":"1413 GMT - BioNTech's share price offers an attractive entry point as the market undervalues the company's cancer drug pipeline potential as well as positive catalysts expected through 2025, Berenberg analysts say. The German biotech stock is trading near its six-month low, which doesn't reflect the potential of its cancer drug candidates, they say in a note. The analysts expect positive trial readouts, particularly for its individualized cancer vaccine platform and its HER2 antibody drug conjugate, to drive higher valuations through 2025. BioNTech's conservative 2025 guidance suggests planned cost-control and productivity measures, the analysts add. Shares fall 1.45% to 88.25 euros. (helena.smolak@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 21, 2025 10:13 ET (14:13 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2521280188"}